SkinMedica, Mass General Hospital Form Accord
Published October 2, 2012
• SkinMedica will collaborate with Massachusetts General Hospital (MGH) for the research and development of pigmentation products, the Carlsbad, CA company announced. The exclusive agreement involves screening and evaluating a library of roughly 40,000 natural extracts made available by the National Cancer Institute for potential applications in pigmentation.
The principal investigator for this collaborative effort is Dr. David Fisher, chief of the Massachusetts General Hospital Department of Dermatology, director of the MGH Cutaneous Biology Research Center and Director of the Melanoma Center at MGH. He is also the Edward Wigglesworth Professor of Dermatology at Harvard Medical School and past president of the Society for Melanoma Research.
Mary Fisher, CEO of SkinMedica. said Dr. Fisher’s “expertise in pigment and the skin’s environmental responses will be invaluable as we together to pursue novel approaches for patients with a variety of pigment related concerns.”
More info: www.skinmedica.com
blog comments powered by Disqus